---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002341"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:58:35.235904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study

## Summary
- Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.
- Company plans to release results of new study on previously untested KRAS mutation shortly; if positive, could support pan-KRAS potential.
- SIL204's lipid-conjugated delivery system validated; overcoming a key barrier for siRNA in solid tumors.
- Company continues to prepare for Phase 2/3 trial initiation in Q2 2026 for KRAS-driven solid tumors.
- Builds on prior efficacy in pancreatic and colorectal cancer models; KRAS mutations occur in ~30% of lung cancers.

## SEC filing metadata
- accession: 0001178913-25-002341
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/0001178913-25-002341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/zk2533417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002341
- JSON: https://secwatch.observer/filing/0001178913-25-002341.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.